Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : REFILE-Moderna chief executive sees pandemic over in a year - newspaper

09/23/2021 | 01:29am EDT

ZURICH, Sept 23 (Reuters) - Moderna Inc Chief Executive Stéphane Bancel thinks the coronavirus pandemic could be over in a year as increased vaccine production ensures global supplies, he told the Swiss newspaper Neue Zuercher Zeitung.

"If you look at the industry-wide expansion of production capacities over the past six months, enough doses should be available by the middle of next year so that everyone on this earth can be vaccinated. Boosters should also be possible to the extent required," he told the newspaper in an interview.

Vaccinations would soon be available even for infants, he said.

"Those who do not get vaccinated will immunize themselves naturally, because the Delta variant is so contagious. In this way we will end up in a situation similar to that of the flu. You can either get vaccinated and have a good winter. Or you don't do it and risk getting sick and possibly even ending up in hospital."

Asked if that meant a return to normal in the second half of next year, he said: "As of today, in a year, I assume."

Bancel said he expected governments to approve booster shots for people already vaccinated because patients at risk who were vaccinated last autumn "undoubtedly" needed a refresher.

Its booster shot had half the dose of the original dose, which meant more of them would be available.

"The volume of vaccine is the biggest limiting factor. With half the dose, we would have 3 billion doses available worldwide for the coming year instead of just 2 billion," he said.

The composition of the booster shot remains the same as the original for this year because Moderna had not had enough time to change it.

"We are currently testing Delta-optimized variants in clinical trials. They will form the basis for the booster vaccination for 2022. We are also trying out Delta plus Beta, the next mutation that scientists believe is likely."

Moderna can use existing production lines for the new variants as for the original COVID-19 vaccine. The price of vaccination will stay the same, he said. (Reporting by Michael Shields Editing by Robert Birsel)


© Reuters 2021
All news about MODERNA, INC.
05:22pStocks rise on strong earnings reports
RE
04:46pMODERNA : Wall St ends up with Goldman; Dow posts biggest weekly rise since June
RE
03:42pJOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Receives FDA Advisory Panel Recommendati..
MT
03:42pMODERNA : NIH's Collins Says FDA Wants to Study Moderna Covid Shot in Kids Longer
MT
03:02pMODERNA : U.S. administers 406.6 mln doses of COVID-19 vaccines - CDC
RE
02:55pFDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
02:44pMODERNA : Wall St climbs after week of strong bank results; market set for weekly gains
RE
02:13pMODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
RE
01:40pPFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
AQ
01:35pEquities Climb Midday With Yields After Surprise Retail Sales Gain
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 5,95x
EV / Sales 2022 5,22x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 324,21 $
Average target price 299,31 $
Spread / Average Target -7,68%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.210.34%133 962
LONZA GROUP AG26.44%57 839
IQVIA HOLDINGS INC.38.89%47 294
SEAGEN INC.-1.38%30 963
CELLTRION, INC.-38.72%25 574
ALNYLAM PHARMACEUTICALS, INC.60.47%24 874